113 related articles for article (PubMed ID: 28670142)
1. Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database.
Jick S; Li L; Gastanaga VM; Liede A; Hernandez RK
Clin Epidemiol; 2017; 9():339-343. PubMed ID: 28670142
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of hypercalcemia of malignancy among cancer patients in the UK: analysis of the Clinical Practice Research Datalink database.
Jick S; Li L; Gastanaga VM; Liede A
Cancer Epidemiol; 2015 Dec; 39(6):901-7. PubMed ID: 26520619
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of hypercalcemia among cancer patients in the United States.
Gastanaga VM; Schwartzberg LS; Jain RK; Pirolli M; Quach D; Quigley JM; Mu G; Scott Stryker W; Liede A
Cancer Med; 2016 Aug; 5(8):2091-100. PubMed ID: 27263488
[TBL] [Abstract][Full Text] [Related]
4. A cross-sectional study to determine the prevalence of calcium metabolic disorder in malignant childhood cancers in patients admitted to the pediatric ward of Vali-Asr Hospital.
Moayeri H; Oloomi Z; Sambo SA
Acta Med Iran; 2011; 49(12):818-23. PubMed ID: 22174172
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis.
Bhandari S; Kumar R; Tripathi P; Chan A; Mudra S; Redman R
Med Oncol; 2019 Sep; 36(10):90. PubMed ID: 31529163
[TBL] [Abstract][Full Text] [Related]
6. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
[TBL] [Abstract][Full Text] [Related]
8. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
[TBL] [Abstract][Full Text] [Related]
10. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Diel IJ; Body JJ; Stopeck AT; Vadhan-Raj S; Spencer A; Steger G; von Moos R; Goldwasser F; Feng A; Braun A
Eur J Cancer; 2015 Jul; 51(11):1467-75. PubMed ID: 25976743
[TBL] [Abstract][Full Text] [Related]
11. Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies.
Cheng C; Kuzhively J; Baim S
Case Rep Endocrinol; 2017; 2017():2608392. PubMed ID: 28168064
[TBL] [Abstract][Full Text] [Related]
12. Hypercalcemia of Malignancy.
Feldenzer KL; Sarno J
J Adv Pract Oncol; 2018; 9(5):496-504. PubMed ID: 31086686
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
[TBL] [Abstract][Full Text] [Related]
15. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients.
Biagini E; Coccolo F; Ferlito M; Perugini E; Rocchi G; Bacchi-Reggiani L; Lofiego C; Boriani G; Prandstraller D; Picchio FM; Branzi A; Rapezzi C
J Am Coll Cardiol; 2005 Oct; 46(8):1543-50. PubMed ID: 16226182
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hypercalcemia in hospitalised patients: effects of "correction" for serum albumin values.
Carnevale V; Pipino M; Antonacci M; Checchia C; D'Alessandro V; Errico M; Greco A; Varriale A
J Endocrinol Invest; 2005 May; 28(5):RC15-7. PubMed ID: 16075918
[TBL] [Abstract][Full Text] [Related]
18. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population.
Li L; Jick S; Breitenstein S; Hernandez G; Michel A; Vizcaya D
Pulm Circ; 2017 Mar; 7(1):126-136. PubMed ID: 28680572
[TBL] [Abstract][Full Text] [Related]
20. Conventional treatment of hypercalcemia of malignancy.
Davidson TG
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S8-15. PubMed ID: 11757206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
